{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:55Z","timestamp":1790821555282,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>With the approval of natalizumab in Europe in 2006, the Austrian Multiple Sclerosis Therapy Registry (AMSTR) was established. Here, we present data from this registry about effectiveness and safety of natalizumab in patients treated up to 14\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients\/methods<\/jats:title>\n                <jats:p>Data retrieved from the AMSTR contained baseline characteristics and biannual documentation of annualised relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score as well as adverse events and reasons for discontinuation on follow-up visits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1596 natalizumab patients (71% women, <jats:italic>n\u2009=\u2009<\/jats:italic>1133) were included in the analysis and the observed treatment duration ranged from 0 to 164\u00a0months (13.6\u00a0years). The mean ARR was 2.0 (SD\u2009=\u20091.13) at baseline, decreasing to 0.16 after 1\u00a0year and 0.01 after 10\u00a0years. A total of 325 patients (21.6%) converted to secondary progressive multiple sclerosis (SPMS) during the observational period. Of 1502 patients, 1297 (86.4%) reported no adverse events (AE) during follow-up visits. The most common reported AEs were infections and infusion-related reactions. John Cunningham virus (JCV) seropositivity was the most common specified reason for treatment discontinuation (53.7%, <jats:italic>n\u2009=\u2009<\/jats:italic>607). There were five confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) with 1 death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The effectiveness of natalizumab in patients with active relapsing\u2013remitting multiple sclerosis (RRMS) could be confirmed in our real-world cohort even after follow-up of up to 14\u00a0years, though after year 10, there were less than 100 remaining patients. A low number of AE were reported in this nationwide registry study, establishing Natalizumab\u2019s favourable safety profile during long-term use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11686-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T12:02:09Z","timestamp":1681905729000},"page":"3779-3786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)"],"prefix":"10.1007","volume":"270","author":[{"given":"Tobias","family":"Monschein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarinah","family":"Dekany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zrzavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-8635","authenticated-orcid":false,"given":"Fritz","family":"Leutmezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Guger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Austrian MS Treatment Registry (AMSTR)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"11686_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J (2019) Treatment of multiple sclerosis \u2014 success from bench to bedside. Nat Rev Neurol 15:53\u201358","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"11686_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ane.12864","volume":"137","author":"M Guger","year":"2018","unstructured":"Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E et al (2018) Real-life clinical use of natalizumab and fingolimod in Austria. Acta Neurol Scand 137(2):181\u2013187","journal-title":"Acta Neurol Scand"},{"issue":"1\u20132","key":"11686_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000479696","volume":"49","author":"S Salhofer-Polanyi","year":"2017","unstructured":"Salhofer-Polanyi S, Cetin H, Leutmezer F, Baumgartner A, Blechinger S, Dal-Bianco A et al (2017) Epidemiology of multiple sclerosis in Austria. Neuroepidemiology 49(1\u20132):40\u201344","journal-title":"Neuroepidemiology"},{"key":"11686_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"L Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013441","journal-title":"Lancet Neurol"},{"issue":"9","key":"11686_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"9","key":"11686_CR6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911\u2013923","journal-title":"N Engl J Med"},{"issue":"6","key":"11686_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","volume":"91","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Spelman T et al (2020) Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 91(6):660\u2013668","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"11686_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D et al (2016) Defining secondary progressive multiple sclerosis. Brain 139(9):2395\u20132405","journal-title":"Brain"},{"issue":"11","key":"11686_CR9","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1007\/s00415-021-10559-w","volume":"268","author":"M Guger","year":"2021","unstructured":"Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S et al (2021) Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. J Neurol 268(11):4303\u20134310","journal-title":"J Neurol"},{"issue":"4","key":"11686_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"issue":"1","key":"11686_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","volume":"83","author":"P O\u2019Connor","year":"2014","unstructured":"O\u2019Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA et al (2014) Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology 83(1):78\u201386","journal-title":"Neurology"},{"key":"11686_CR12","doi-asserted-by":"publisher","first-page":"101863","DOI":"10.1016\/j.msard.2019.101863","volume":"39","author":"J Foley","year":"2020","unstructured":"Foley J, Carrillo-Infante C, Smith J, Evans K, Ho PR, Lee L et al (2020) The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord 39:101863","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"11686_CR13","volume":"87","author":"DI Campagnolo","year":"2016","unstructured":"Campagnolo DI, Ho P-R, Patel R, Chang I, Subramanyam M, Koendgen H et al (2016) Four-year longitudinal index stability data from STRATIFY-2 support the clinical utility of index for risk stratification of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 87(2):e25","journal-title":"Neurology"},{"key":"11686_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83:278\u2013286","journal-title":"Neurology"},{"issue":"3","key":"11686_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1352458507084264","volume":"14","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Devonshire V (2008) Natural history of secondary-progressive multiple sclerosis. Mult Scler 14(3):314\u2013324","journal-title":"Mult Scler"},{"issue":"3","key":"11686_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awl007","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(3):606\u2013616","journal-title":"Brain"}],"updated-by":[{"DOI":"10.1007\/s00415-023-11784-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T13:03:20Z","timestamp":1689253400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["11686"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11686-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-023-11784-1","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-023-11784-1","URL":"https:\/\/doi.org\/10.1007\/s00415-023-11784-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Altmann has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Merck, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting from Biogen. He received a research grant from Quanterix International and was awarded a sponsorship from Biogen, Merck, Sanofi-Genzyme, Roche, and Teva to programme a smartphone application for people with MS. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Biogen, Bionorica, Celgene\/BMS, GSK, Janssen-Cilag, MedDay, Merck, Novartis, Roche, Sanofi Aventis\/Genzyme, TG Therapeutics and TEVA. His institution has received financial support in the last 2\u00a0years by unrestricted research grants (Biogen, Celgene\/BMS, Novartis, Roche, Sanofi Aventis\/Genzyme, TEVA) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Aventis\/Genzyme, TEVA. Gabriel Bsteh has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received research grants from Celgene\/BMS and Novartis. Sarinah Dekany declares no conflict of interest with respect to the study and data presented in this paper. Christian Enzinger received funding for travel and speaker honoraria from Biogen, Bayer, Celgene, Merck, Novartis, Roche, Shire, Genzyme and Teva Pharmaceutical Industries Ltd.\/sanofi-aventis; research support from Merck Serono, Biogen, and Teva Pharmaceutical Industries Ltd.\/sanofi-aventis; serving on scientific advisory boards for Bayer, Biogen, Celgene, Merck, Novartis, Roche and Teva Pharmaceutical Industries Ltd.\/sanofi-aventis. Michael Guger received support and honoraria for research, consultation, lectures and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire, and TEVA ratiopharm. J\u00f6rg Kraus received consulting and\/or research funding and\/or educational support from Almirall, Bayer, Biogen, Celgene\/ Bristol Myers Squibb, MedDay, Medtronic, Merck, Novartis, Roche, Sanofi-Aventis, Shire, and TEVA ratiopharm. Barbara Kornek has received honoraria for lecturing or consulting from Biogen, BMS-Celgene, Merck, Novartis, Johnson&Johnson, Sanofi-Genzyme, Roche, and Teva. Fritz Leutmezer has participated in meetings sponsored by, received speaker honoraria or travel funding or unrestricted scientific grants from Actelion, Biogen, Celgene, Med Day, Merck, Novartis, Roche, Sanofi-Genzyme, Schering, and Teva. Tobias Monschein has participated in meetings sponsored by or received travel funding from Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Markus Ponleitner has participated in meetings sponsored by or received travel funding from Amicus, Merck, Novartis and Sanofi-Genzyme. Paulus Stefan Rommer received honoraria for lectures or consultancy from AbbVie, Alexion, Allmiral, Biogen, Daiichi-Sankyo, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, Teva. He received research grants from Amicus, Biogen, Merck, and Roche. Franziska Di Pauli has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Almirall, Bayer, Biogen, Celgene, Janssen, Merck, Novartis, Sanofi-Genzyme, Roche, and Teva. Her institution has received research grants from Roche. Tobias Zrzavy has participated in meetings sponsored by or received travel funding from Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Ethics Committee of the Medical University of Vienna (EC number 1448\/2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}